PDT Partners’s ANI Pharmaceuticals ANIP Stock Holding History

PDT Partners’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.76M	Hold	45,442	–	–	0.2%	162
2026 Q1	$3.49M	Hold	45,442	–	–	0.21%	162
2025 Q4	$3.59M	Hold	45,442	–	–	0.23%	159
2025 Q3	$4.16M	Hold	45,442	–	–	0.26%	138
2025 Q2	$2.97M	Buy	+45,442	New	+$2.96M	0.17%	211
2015 Q3	–	Sell	-7,500	Closed	-$465K	–	1252
2015 Q2	$465K	Sell	7,500 -9,700	-56%	-$577K	0.01%	998
2015 Q1	$1.08M	Sell	17,200 -2,500	-13%	-$152K	0.03%	768
2014 Q4	$1.11M	Buy	19,700 +3,900	+25%	+$172K	0.11%	216
2014 Q3	$447K	Buy	15,800 +3,200	+25%	+$95.9K	0.01%	977
2014 Q2	$434K	Buy	12,600 +3,400	+37%	+$107K	0.01%	1069
2014 Q1	$288K	Buy	+9,200	New	+$244K	0.01%	1125

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PDT Partners's ANIP Position: Q2 2026 in Review

PDT Partners held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 45,442 shares worth $3.76M. The position accounts for 0.2% of the portfolio, ranked #162.

PDT Partners first reported a position in ANIP in Q1 2014 and has held it in 11 quarters since. The position peaked at $4.16M in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

PDT Partners held 45,442 shares of ANI Pharmaceuticals worth $3.76M as of Q2 2026.
PDT Partners left its ANI Pharmaceuticals share count unchanged in Q2 2026.
ANI Pharmaceuticals made up 0.2% of PDT Partners's portfolio in Q2 2026, its #162 holding.
PDT Partners first reported a position in ANI Pharmaceuticals in Q1 2014 and has held it in 11 quarters since.
PDT Partners's ANI Pharmaceuticals position peaked at $4.16M in Q3 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.